The role of ADP receptor (P2Y12) in the development of transplant arteriosclerosis

ADP受体（P2Y12）在移植动脉硬化发展中的作用

• 批准号: 23659281
• 负责人: UMEMURA Kazuo
• 金额: $ 2.41万
• 依托单位: Hamamatsu University School of Medicine
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Challenging Exploratory Research
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23659281/
• 关键词: ADP (P2Y12) 受容体; 移植後動脈硬化; 平滑筋様細胞; 遊走; 分化; P2Y12受容体; 遊走能; 血管平滑筋細胞; P2Y12

The role of ADP (P2Y12) receptor on smooth muscle like cells (SMLCs) in the development of transplant arteriosclerosis (TA) was examined. A stable ADP analog, 2-methylthio-ADP-induced cell migration was significantly decreased in P2Y 12-deficient-SMLCs. In addition, the migration was significantly decreased by the pretreatment with wortmannin (phosphoinositide 3-kinase [PI3K] inhibitor) or PD98059 (extracellular signal-regulated kinase [ERK] inhibitor). However, the differentiation of bone marrow-derived cells into SMLCs was not associated with P2Y12 receptors. Thus, the migration of SMLCs mediated by P2Y12 receptors may play an important role in the development of TA, via PI3K-Akt and ERK signaling pathways.

研究了平滑肌样细胞 (SMLC) 上 ADP (P2Y12) 受体在移植动脉硬化 (TA) 发展中的作用。稳定的 ADP 类似物 2-甲硫基-ADP 诱导的细胞迁移在 P2Y 12 缺陷型 SMLC 中显着减少。此外，用渥曼青霉素（磷酸肌醇3激酶[PI3K]抑制剂）或PD98059（细胞外信号调节激酶[ERK]抑制剂）预处理显着减少了迁移。然而，骨髓源性细胞向 SMLC 的分化与 P2Y12 受体无关。因此，P2Y12 受体介导的 SMLC 迁移可能通过 PI3K-Akt 和 ERK 信号通路在 TA 的发展中发挥重要作用。

项目成果

ADP受容体を介した骨髄平滑筋細胞の遊走と遺伝子発現に対する影響

ADP 受体介导的对骨髓平滑肌细胞迁移和基因表达的影响

• 发表时间: 2011
• 作者: 松本祐直;原田恒介;梅村和夫．
• 通讯作者: 梅村和夫．

ADP receptor-mediated differentiation of bone-marrow-derived cells into smooth muscle-like cells.

ADP 受体介导的骨髓来源细胞分化为平滑肌样细胞。

• 发表时间: 2012
• 作者: Yuji Matsumoto;Kosuke Harada;Kazuo Umemura.
• 通讯作者: Kazuo Umemura.